GAPS IN CARDIOVASCULAR MEDICATION TAKING - THE TIP OF THE ICEBERG

被引:31
作者
RUDD, P
RAMESH, J
BRYANTKOSLING, C
GUERRERO, D
机构
[1] the Department of Medicine, Stanford University Medical Center
[2] the Department of Medicine, Kaiser Permanente Medical Center, Santa Clara
[3] the Division of Product Safety and Compliance (Unified Corporate Safety Database), Syntex Corporation, Palo Alto, California
[4] the Stanford University School of Medicine, Stanford
关键词
MEDICATION COMPLIANCE; DRUG THERAPY; CARDIOVASCULAR DISEASE; ELECTRONIC MONITORING; PREDICTORS; COMPLIANCE MEASURES; MORBIDITY; MORTALITY;
D O I
10.1007/BF02598282
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: To search for major gaps in medication-taking behavior predisposing patients to cardiovascular morbidity and mortality. Design: Convenience sample; cohort prospectively followed for less-than-or-equal-to 5 months. Setting: General internal medicine and cardiology clinics in a university medical center. Patients: From among 893 patients, the authors identified 132 eligible individuals and entered 33 subjects (25%) with chronic cardiovascular conditions, 1 - 3 chronic oral medications for these conditions, overall regimen of less-than-or-equal-to 6 drugs, regular visits at 1 -3-month intervals, literacy in English, willingness to use electronic monitors, and physician permission to participate. Outcome measures: Medication compliance rates and patterns by patient self-report, physician estimates, pill count, and electronic monitoring of pill vial opening. Results: Despite moderately complex regimens (5.4 +/- 0.5 pills daily; range 1 - 11), most subjects took most medications according to the prescription: median intervals between pill vial openings were 1.00, 0.50, and 0.43 days for once, twice, and three times daily dosing, respectively. Medication-taking gaps of greater-than-or-equal-to 2 times the prescribed interdosing interval occurred for 48% of the patients. Patients' dosing patterns often produced ''uncovered'' intervals (mean duration 3.7 days, range 0 - 2 5) with doubtful pharmacologic effectiveness. These lapses were underestimated by patients and poorly perceived by their treating physicians, despite familiarity with their care. Baseline sociodemographic, psychosocial, medical system, or clinical characteristics did not predict the patterns or degrees of medication noncompliance. Conclusions: Major treatment gaps occur frequently, even in carefully selected ambulatory populations, and generally escape detection. The compliance patterns and gaps may contribute to reported excesses of cardiovascular morbidity and mortality.
引用
收藏
页码:659 / 666
页数:8
相关论文
共 40 条
[1]  
Mushlin A.I., Appel F.A., Diagnosing patient noncompliance, Arch Intern Med, 137, pp. 318-21, (1977)
[2]  
Gilbert J.R., Evans C.E., Haynes R.B., Tugwell P., Predicting compliance with a regimen of digoxin therapy in family practice, Can Med Assoc J, 123, pp. 119-22, (1980)
[3]  
Caron H.S., Compliance: the case for objective measurement, J Hypertens, 3, pp. 11-7, (1985)
[4]  
Kass M.A., Gordon M., Meltzer D.W., Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy?, Am J Ophthalmol, 101, pp. 524-30, (1986)
[5]  
Eisen S.A., Woodward R.S., Miller D., Spitznagel E., Windham C.A., The effect of medication compliance on the control of hypertension, J Gen Intern Med, 2, pp. 298-305, (1987)
[6]  
Cramer J.A., Mattson R.H., Prevey M.L., Scheyer R.D., Ouellette V.L., How often is medication taken as prescribed? A novel assessment technique, JAMA, 261, pp. 3273-7, (1989)
[7]  
Rudd P., Byyny R.L., Zachary V., Et al., The natural history of medication compliance in a drug trial: limitations of pill counts, Clin Pharmacol Ther, 46, pp. 169-76, (1989)
[8]  
Cramer J.A., Scheyer R.D., Mattson R.H., Compliance declines between clinic visits, Arch Intern Med, 150, pp. 1509-10, (1990)
[9]  
Eisen S.A., Miller D.K., Woodward R.S., Spitznagel E., Przybeck T.R., The effect of prescribed daily dose frequency on patient medication compliance, Arch Intern Med, 150, pp. 1881-4, (1990)
[10]  
Kruse W., Weber E., Dynamics of drug regimen compliance—its assessment by microprocessor-based monitoring, Eur J Clin Pharmacol, 38, pp. 561-5, (1990)